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Prasun J MishraAbstract
Cumulating data suggest that small noncoding-RNAs such as microRNAs (miRNAs) can be utilized as potential
biomarkers for the diagnosis and prognosis of a variety of diseases such as cancer, neurological disorders,
cardiovascular disease and Type-II diabetes, etc. MiRNAs can be utilized not only for monitoring of treatments but
also for patient stratifications. The Tenth Annual miRNA as Biomarkers and Diagnostics conference, 2014, organized
in Boston, MA, was primarily focused on recent advancements in the field of miRNA in the early detection of
disease, monitoring tumor growth/progression and its potential for precision medicine. This article summarizes
findings presented in the miRNA biomarker as cancer diagnostics session. The overarching projections from this
and other sessions were that miRNAs are now well established as regulators of tumorigenesis and can be utilized
not only as potential biomarkers for the diagnosis and prognosis of a disease but also are useful in patient
stratifications and treatment response.
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The data presented at the microRNA (miRNA) bio-
marker as cancer diagnostics session clearly suggested
that miRNA profiling has been useful in identifying
predictive miRNA signatures associated with tumor
growth/progression of various cancer types such as
pancreatic cancer, colorectal cancer, osteosarcoma as well
as clear cell renal cell carcinoma. Changes of specific
miRNAs can be detected in tissues utilizing a slide-based
staining assay and from circulating tumor cells from the
blood sample as well as in the urine, presenting a noninva-
sive way to detect miRNAs. Furthermore, detection of
exosomic miRNAs in the tumor microenvironment may
provide better tools for development of new personalized
treatments for cancer patients. Moreover, detection of
miRNA‐polymorphisms and miRNA variants may help
further improve diagnosis, treatment and prognosis in
patients and has profound implications in the fields of
pharmacogenomics and precision medicine.Correspondence: mishrapj@mail.nih.gov
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unless otherwise stated.Small noncoding-RNAs such as microRNAs (miRNAs)
are emerging as prominent disease associated biomar-
kers and can be utilized not only for patient stratifi-
cations but also for monitoring of treatments (i.e. for
diagnosis and prognosis). To discuss this, The Tenth
Annual microRNA as Biomarkers and Diagnostics con-
ference (March 17–18, 2014), organized in Boston, MA,
USA brought over 100 representatives from academia,
government, clinical laboratories and industry and com-
prised of 20 presentations (101). The conference broadly
covered topics in the area of 1) miRNA biomarkers in
drug development; 2) miRNA biomarkers as cancer
diagnostics; and 3) miRNA as disease biomarkers (101).
This article summarizes the session regarding miRNA
biomarker as cancer diagnostics.
Chairperson’s opening remarks
Prasun J. Mishra, Ph.D., (US Department of Health and
Human Services, National Cancer Institute, National
Institutes of Health) opened the session by describing
the need for predictive biomarkers in cancer progres-
sion/prognosis and why miRNAs are promising candi-
dates in predicting drug response. MiRNAs are smallhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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are emerging as a new class of biomarkers. The cancer re-
search field has been at the forefront of advancing miRNA
biomarker field for over a decade now. This has been
made possible, not only due to the availability of the
tumor tissue samples in the clinic, but also recent ad-
vancements in the field of miRNA detection and sequen-
cing. MiRNAs are now well established as regulators of
tumorigenesis. In cancer, miRNA expression variations are
evident across different stages of cancer progression [1].
In malignancy, miRNA expression is altered (overex-
pressed/underrepresented) [2]. Overexpressed miRNAs in
cancer may act like oncogenes by down-regulating tumor
suppressor genes. Vice versa is also true, down modulated
tumorsuppressor-like miRNAs result in upregulation of
oncogenes there by functioning as tumor suppressors.
Hence, in a malignant tumor, the oncogenic miRNAs are
upregulated and tumor suppressor miRNAs are downreg-
ulated. These miRNAs can be exploited as potential bio-
markers. miRNAs are also tissue specific and may be
unique identifiers of tumor type and its origin [3]. An in-
creasing number of miRNAs are now identified and uti-
lized as prognostic miRNAs to predict drug response.
The importance and the uniqueness of this session
were also emphasized. This particular session was de-
signed to cover recent advancements in the miRNA as
biomarker and cancer diagnostics field. The speakers
discussed utility of non-coding RNA variants to preci-
sion medicine (Prasun Mishra) as well as role of miRNA
in tumor microenvironment (Muller Fabbri). The session
also highlighted utility of miRNAs profiling in monitoring
tumor growth/progression of pancreatic cancer (Lorenzo
Sempere), colorectal cancer (Jingfang Ju), circulating os-
teosarcoma cells (Benjamin Ory) and clear cell renal cell
carcinoma (Huiqing Wu) and its utility as a biomarker for
precision medicine.
MicroRNA variants as molecular diagnostics and
prognostic tools
Prasun J. Mishra (US Department of Health and Human
Services, National Cancer Institute, National Institutes
of Health) described recent advances in the field of
miRNA polymorphisms and their implications to preci-
sion medicine. Recent advancements in microRNA field
suggest that genetic variation or polymorphisms present
in the miRNA pathway are associated with the progno-
sis/progression of diseases and drug responses and are
emerging as powerful tools to study biology of diseases
[4-6]. MicroRNA polymorphisms (miR‐polymorphisms)
can be defined as polymorphisms (SNPs, chromosomal
changes, epigenetic defects, mutations, alterations and
variations) that may potentially interfere with miRNA‐
mediated regulation of cellular functions and can be
present not only in the miRNA target gene but also inpri‐, pre‐, mature‐miRNA sequences, in the genes in-
volved in miRNA biogenesis and in miRNA cis‐regula-
tory elements (e.g. promoter) [7]. A polymorphism in
mature miRNAs may affect expression of several genes
and have serious consequences, whereas a polymorph-
ism in miRNA target site may be more target and/or
pathway specific [7]. For example, mir-24 regulates ex-
pression of anti-cancer drug methotrexate (MTX) target
dihydrofolate reductase (DHFR) by binding to its 3′
UTR; a SNP in DHFR 3′ UTR results in loss of the
miR-24 function (miRSNP), an increase in DHFR ex-
pression and MTX-chemoresistance [4]. Thus, in addition
to gene amplification causing DHFR overexpression [8],
loss of miRNA function due to a miRSNP represents a
new mechanism of target overexpression and drug resist-
ance [8] and establishes a miRNA-drug resistance link [8].
In a follow up report, miR-24 was demonstrated to act as
a p53-independent tumor suppressor miRNA, and loss of
mir-24 function due to the miRSNPs not only confers
drug resistance but also imparts a growth advantage to
immortalized cells and induces neoplastic transformation
[6]. Thus, recent advances in the miRNA field have led to
the understanding of entirely new mechanisms of cellular
transformation and drug-resistance caused by loss of
miRNA function by an miRNA variant (miRSNP/miR-
polymorphisms) [4-6]. Moreover, the discovery of the role
of miRNA in drug resistance and miR‐polymorphisms to
predict drug response has led to the development of a
new field in biomedical science called miRNA pharma-
cogenomics, a study of the miRNAs and miR‐polymor-
phisms affecting expressions of drug target genes, to
predict drug behavior and to improve drug efficacy. Detec-
tion of miRNA‐polymorphisms can potentially improve
diagnosis, treatment and prognosis in patients and has
profound implications in the fields of pharmacogenomics
and precision medicine [9].
Role of exosomic miRNAs in the tumor
microenvironment
Muller Fabbri (Pediatrics and Molecular Microbiology &
Immunology, University of Southern California Keck
School of Medicine, Children’s Hospital Los Angeles)
described role of exosomic miRNA in tumor microen-
vironment and it’s implication to precision medicine.
Cancer is a genetic disease and an increasing evidence
indicates that not only cancer cells but also surrounding
cells, forming the so-called “tumor microenvironment”,
play a key role in cancer biology [10]. MiRNAs are also
secreted by cancer cells in the surrounding tumor mi-
croenvironment, within microvesicles (called exosomes).
Exosome-contained miRNAs (namely, miR-21 and miR-
29a) can be engulfed by the immune cells surrounding can-
cer cells and they can bind to Toll-like Receptor 8 (TLR8)
present in the immune cells [10]. As a consequence, TLR8
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(IL-6) and tumor necrosis factor alpha (TNF-alpha), which
increase tumor growth and metastatic potential [11]. A
better understanding of this novel mechanism of miRNA
action will contribute to the development of new person-
alized treatments for cancer patients [10].
Tissue slide-based microRNA diagnostics
Lorenzo F. Sempere (Center for Personalized Medicine,
Van Andel Research Institute) described a slide based
miRNA diagnostics tool for pancreatic cancer. MiRNA
diagnostics is an emerging area of prognostic and pre-
dictive indicators in cancer medicine. Dr. Sempere pre-
sented his study focused on the role of miRNAs in
initiation and progression of pancreatic cancer [12]. Re-
cent studies in the pancreatic cancer field have shown
that there are changes in the levels of miRNAs between
normal and tumor tissues [13]. Tissue slide-based assays
are routine diagnostic procedures in clinical laboratories
to guide treatment options. This study implemented a
fully automated tissue slide-based staining assay in a
CLIA-certified environment utilizing in situ hybridiza-
tion to identify specific miRNAs alterations in the pan-
creas of mouse models that develop pancreatic cancer.
Since pancreatic tissue is composed of different cell
types and only some of these cells are susceptible to de-
velop cancer, it is important to know if these miRNA
changes occur within the cancer-prone cells. Hence this
study aimed to determine whether neutralizing these
miRNA changes affect the growth and survival proper-
ties of the cancer cells. Potential utility of the assay were
described in measuring levels and cellular compartment
of miRNA expression in solid tumors and potential diag-
nostic applications of salient miRNA examples (includ-
ing miR-21 and miR-34a) were discussed [12].
MicroRNAs as biomarkers in colorectal cancer
Jingfang Ju (Translational Research, Pathology, Stony
Brook University) described recent developments in the
area of miRNAs as biomarkers in colorectal cancer.
5-Fluorouracil based chemotherapy (e.g. FOLFOX) is the
standard chemotherapeutic regimen for treating ad-
vanced stage colorectal cancer. Chemoresistance is the
major reason for the failure of treating advanced colo-
rectal cancer [14]. MiRNA based therapeutics, diagnosis
and prognosis may emerge in the near future to benefit
cancer patients. Several miRNAs were found to be as-
sociated (miR-192, miR-215, miR-140, miR-129, let-7,
miR-181b, miR-200 s) with chemoresistance by regulat-
ing key cell death pathways such as apoptosis and au-
tophagy. Several important miRNA were described that
regulate targets such as Bcl2, thymidylate synthase, dihy-
drofolate reductase, histone deacetylase, and E2F. For ex-
ample, miR-215 was identified to suppress the expressionof both thymidylate synthase and dihydrofolate reductase
[15]. In addition, the expression of miR-215 was directly
regulated by p53. The expression of miR-215 was signifi-
cantly associated with colorectal cancer patient survival.
Another miRNA, miR-140, was found to modulate
chemosensitivity by suppressing HDAC4 expression,
and the levels of miR-140 and miR-215 were elevated
in colon cancer stem cells [16]. Furthermore, miR-194
was identified to regulate BMI-1 protein expression
(BMI-1 is involved in epithelial to- mesenchymal transi-
tion) [17]. Moreover, miR-502 regulates autophagy in
colon cancer by targeting Rab1B [18]. Taken together,
these miRNAs can be utilized in predicting patient’s prog-
nosis and survival.
MicroRNA profiling of circulating tumor cells from
osteosarcoma
Benjamin Ory (Therapy Primary Bone Tumor, Nantes
Medical School, INSERM) described a miRNA profiling
method [19] of circulating tumor cells. Through the iso-
lation of the rare circulating tumor cells (CTCs) in the
blood stream, Dr. Ory and his group uncovered some
basic functional roles of the miRNAs in the regulation of
pathways involved in the cellular migration and invasion,
responsible for the metastasis dissemination of osteosar-
coma (unpublished). This study identified a panel of new
candidate miRNAs as predictive biomarkers for osteo-
sarcoma metastasis from the analysis of blood samples.
A miRNA signature to predict metastatic clear cell
renal cell carcinoma
Huiqing Wu (Pathology, City of Hope National Medical
Center, Beckman Research Institute) described a miRNA
signature to predict clear cell renal carcinoma. Using
frozen tissue cohorts, microarray technology and risk
score method, Dr. Wu’s group identified a 4-miRNA sig-
nature associated with clear cell renal cell carcinoma
(ccRCC) metastasis and prognosis [20,21]. The signature
can be validated on a formalin-fixed paraffin-embedded
(FFPE) tissue-specific and RT-PCR based assay. The
gene signature was further validated in an FFPE tissue
cohort of 222 cases of primary ccRCC, with an overall
sensitivity and specificity of 70% and 76%, respectively.
The sensitivity and specificity for predicting metastasis
from stage I and II patients were 59% and 74%, respect-
ively. The values for stage III patients were 80% and
83%. The signature was associated with the patient’s
cancer-specific survival and can be utilized as a predict-
ive biomarker.
Conclusion
The overarching projections from this and other sessions
were that miRNAs are now well established as regula-
tors of tumorigenesis and can be utilized not only as
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of a disease but also are useful in patient stratifica-
tions and treatment response [22]. The data presented
at this session clearly suggested that miRNAs profiling
has been useful in identifying predictive miRNA signa-
tures associated with tumor growth/progression of vari-
ous cancer types such as pancreatic cancer, colorectal
cancer, osteosarcoma as well as clear cell renal cell
carcinoma. Changes of specific miRNAs can be detected
in tissues utilizing a slide-based staining assay and from
circulating tumor cells from the blood sample as well as
in the urine, presenting a noninvasive way to detect
miRNAs. Furthermore, detection of exosomic miRNAs
in the tumor microenvironment may provide better
tools for development of new personalized treat-
ments for cancer patients. Moreover, detection of miRNA‐
polymorphisms and miRNA variants may help further
improve diagnosis, treatment and prognosis in patients
and has profound implications in the fields of pharmaco-
genomics and precision medicine.
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